The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 27633969 · doi:10.1186/s12879-016-1823-5
What was done
A systematic review and meta-analysis evaluated the efficacy of thymosin α1 (Tα1) as an immunomodulatory therapy for sepsis. Authors searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and Chinese, Japanese, and Korean databases (CBM, VIP, CNKI, WANFANG, ICHUSHI). Nineteen randomized controlled trials (RCTs) met inclusion criteria.
What was found
- Mortality (10 RCTs, 530 patients): Significantly decreased in the Tα1 group compared with control (RR 0.59, 95% CI 0.45 to 0.77, p = 0.0001). Subgroup analysis showed no difference between two dosages (RR 0.59, 95% CI 0.43 to 0.81 vs RR 0.59, 95% CI 0.35 to 0.98). - APACHE II score (9 RCTs, 489 patients): Tα1 once daily significantly decreased scores (SMD -0.80, 95% CI -1.14 to -0.47, p < 0.0001), while twice daily showed no effect (SMD 0.30, 95% CI -0.10 to 0.70, p = 0.14). - Non-significant clinical outcomes: Length of ICU stay (SMD -0.52, 95% CI -1.06 to 0.11, p = 0.06), multiple organ failure incidence (SMD -0.49, 95% CI -1.09 to 0.11, p = 0.11), and duration of mechanical ventilation (SMD -0.37, 95% CI -0.90 to 0.17, p = 0.17). - Immune markers: HLA-DR levels increased significantly with Tα1 (8 studies, 721 patients; SMD 1.23, 95% CI 0.28 to 2.18, p = 0.01). Beneficial effects were reported for CD3, CD4, IL-6, IL-10, and TNF-α, but exact values were not provided in the abstract.
Why it matters
Thymosin α1 shows potential to reduce mortality and improve immune markers in sepsis patients. However, the evidence base is fragile and insufficient to guide clinical practice without larger, rigorous trials.
Limits
The quality of evidence is low due to small sample sizes across included trials and inadequate adherence to standardized RCT reporting guidelines. Secondary clinical outcomes (ICU length of stay, duration of mechanical ventilation, multiple organ failure) were not significantly improved. Exact effect sizes for cytokine and lymphocyte subsets were omitted from the abstract.
Cited by
- supports Thymosin alpha-1 provides immune system support.